VALORACIÓN MÉDICO LEGAL DEL CONSUMO DE LA MARIHUANA SINTÉTICA

Catalina Hernández Calderón

Catalina Hernández Calderón Médica residente Departamento de Medicina Legal.

Palabras clave: Marihuana sintética, cannabinoides sintéticos, Spice K2, sustancias psicoactivas, muerte por consumo de Drogas

Resumen

La marihuana sintética es una sustancia que ha incrementado su consumo en los últimos años y que conlleva a múltiples implicaciones en la salud de las personas que la utilizan. Este artículo se basa en identificar los principales formas de uso, los síntomas de los evaluados, la fisiopatología de estas sustancias y los riesgos y consideraciones para el manejo de pacientes que consumen cannabinoides sintéticos, así como los criterios Médico Legales que se deben tener presentes en el momento de realizar una valoración de evaluados que utilizan alguna sustancia en la Clínica Médico Forense y en el momento de realizar una autopsia Médico Legal en particular cuando existe la historia reciente del consumo de la marihuana sintética.

Citas

1) Annelies Cannaert et al. (2016). Detection and Activity Profiling of Synthetic Cannabinoids and Their Metabolites with a Newly Developed Bioassay. Analytical Chemistry, 88, 11476-11485.

2) Szilvia Kassai. (2017). Assessing the experience of using synthetic c

3) annabinoids by means of interpretative phenomenological analysis. Harm Reduction Journal, 14, 1-10.

4) Moustafa Elsheshtawy et al. (2016). Synthetic Marijuana Induced Acute Nonischemic Left Ventricular Dysfunction. Case Reports in Cardiology, 1, 1-4

5) John Samaan at al. (2016). Synthetic Cannabis Overdose and Withdrawal in a Young Adult: A Case Report, Commentary on Regulation, and Review of the Literature. Case Reports in Psychiatry, 3640549, 1-7.

6) Heather B. Clayton at al. (2017). Health Risk Behaviors With Synthetic Cannabinoids Versus Marijuana. American Academy of Pediatrics, 139, 4.

7) Andrew L. Ninnemann et al. (2017). Longitudinal Predictors of Synthetic Cannabinoid Use in Adolescents. American Academy of Pediatrics, 139, 1-7.

8) Ziva D. Cooper. (2016). Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. Curr Psychiatry Rep, 52, 1-19.

9) Daniéle Debruyne, Reynald Le Boisselier. (2015). E merging drugs of abuse: current perspectives on synthetic cannabinoids. Substance Abuse and Rehabilitation, 6, 113-119.

10) Michael B. Gatch, Michael J. Forster. (2014). Δ9-Tetrahydrocannabinol-Like Discriminative Stimulus Effects of Compounds Commonly Found in K2/Spice. Behav Pharmacol, 25 (8), 750-757.

11) Marisol S. Castaneto. (2014). Synthetic Cannabinoids: Epidemiology, Pharmacodynamics, and Clinical Implications. Drug Alcohol Depend, 12, 1-60.

12) Kathryn A. Seely et al. (2013). Forensic investigation of K2, Spice, and ‘‘bath salt’’ commercial preparations: A threeyear study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Science International, 233, 416-422.

13) Christopher D. Rosenbaum at al. (2012). Here Today, Gone Tomorrow…and Back Again? A Review of Herbal Marijuana Alternatives (K2, Spice), Synthetic Cathinones (Bath Salts), Kratom, Salvia divinorum, Methoxetamine, and Piperazines. J. Med. Toxicol, 8, 15-32.

14) Dolkar Sherpa et al. (2015). Synthetic cannabinoids: the multi-organ failure and metabolic derangements associated with getting high. Journal of Community Hospital Internal Medicine Perspectives, 27540, 1-6.

15) Regan A. Baum et al. (2017). Suspected Synthetic Cannabinomimetic Intoxication: Case Series and Review. Journal of Pharmacy Practice, 1, 1-6.

16) Piotr Adamowicz at al. (2017). The effects of synthetic cannabinoid UR-144 on the human body—A review of 39 cases. Elsevier, 9, 31-34.

17) Valérie Wolff et al. (2017). Strokes are possible complications of cannabinoids use. Elsevier, 1, 1-9.

18) Derya Guzel et al. (2017). Alterations of the hematologic cells in synthetic cannabinoid users. J Clin Lab Anal., 1, 1-7.

19) Benjamin M. Ford et al. (2017). Synthetic Pot: Not Your Grandfather’s Marijuana. Trends in Pharmacological Sciences, 38, 257-276.

20) Amandine Scocard. (2016). Cannabinoïdes desynthèse: une nouvelle matrice des addictions. ElsevierMasson, 1, 1-12.

21) Manisha Kak et al. (2016). Buzz Juice: Neurological sequelae of synthetic cannabinoids. Journal of Clinical Neuroscience, 1, 1-2.

22) Brooke Mills et al. (2015). Synthetic Cannabinoids. The American Journal of the Medical Sciences, 350, 59-62.

23) Brooke Mills et al. (2015). Synthetic Cannabinoids. The American Journal of the Medical Sciences, 350, 59-62.

24) Robert J. Tait et al. (2016). A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology, 54, 1-13.